Manufacturers of pharmaceuticals, medical devices, and other health products and related trade associations spent $182 million on federal lobbying from January 2005 through June 2006, according to a report issued April 2.
The report, by the Center for Public Integrity, said much of the money was spent on lobbying that targets issues such as patent protection, restrictions on imports of lower-priced Canadian drugs, and the Medicare Prescription Drug Improvement and Modernization Act (which guarantees Medicare-eligible patients a prescription drug benefit while barring the federal government from negotiating drug prices). The Center for Public Integrity is a nonpartisan group based in Washington, DC, that does investigative reporting and research on public policy issues.
Mitka M. Influence or Education?. JAMA. 2007;297(18):1970. doi:10.1001/jama.297.18.1970-b